LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Начало・Списък с акции・Certara Inc

Certara Inc

Затворен

СекторЗдравеопазване

5.11 9.42

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.58

Максимум

5.24

Ключови измерители
By Trading Economics
Приходи	-2.9M -8.8M
Продажби	3.3M 107M
P/E Средно за сектора	100.714 49.701
EPS	0.09
Марж на печалбата	-8.196
Служители	1,515
EBITDA	-8.9M 23M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+75.6% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-89M 709M
Предишно отваряне	-4.31
Предишно затваряне	5.11

Настроения в новините

By Acuity

50%

159 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

11.27 / 12.79 Подкрепа & съпротива

Certara Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.05.2026 г., 23:31 ч. UTC

Горещи акции

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20.05.2026 г., 22:52 ч. UTC

Значими двигатели на пазара

Osisko Shares Fall on Planned Convertible Notes Offering

20.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20.05.2026 г., 23:44 ч. UTC

Печалби

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20.05.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.05.2026 г., 23:17 ч. UTC

Пазарно говорене

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20.05.2026 г., 23:15 ч. UTC

Пазарно говорене

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20.05.2026 г., 23:14 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20.05.2026 г., 23:02 ч. UTC

Пазарно говорене

KMD Brands Faces Two Testing Hurdles -- Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

20.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.05.2026 г., 22:51 ч. UTC

Пазарно говорене

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20.05.2026 г., 22:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.05.2026 г., 22:27 ч. UTC

Пазарно говорене

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20.05.2026 г., 22:14 ч. UTC

Пазарно говорене

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20.05.2026 г., 22:10 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20.05.2026 г., 22:00 ч. UTC

Печалби

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20.05.2026 г., 21:38 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20.05.2026 г., 21:27 ч. UTC

Печалби

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20.05.2026 г., 21:20 ч. UTC

Печалби

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20.05.2026 г., 21:19 ч. UTC

Печалби

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20.05.2026 г., 21:18 ч. UTC

Печалби

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20.05.2026 г., 21:17 ч. UTC

Печалби

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20.05.2026 г., 21:16 ч. UTC

Печалби

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Certara Inc Прогноза

Ценова цел

By TipRanks

75.6% нагоре

12-месечна прогноза

Среден 8.06 USD 75.6%

Висок 10 USD

Нисък 6 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Certara Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Certara Inc през последните 3 месеца.

Техническа оценка

By Trading Central

11.27 / 12.79Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Настроение

By Acuity

159 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.